Double maintains 3 strategies that include NEO - NeoGenomics, Inc.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -21.27% | $23.98B | +34.66% | 1.10% |
CME | -17.85% | $99.01B | +39.76% | 3.87% |
ED | -16.34% | $35.36B | +9.76% | 3.39% |
AEP | -14.01% | $54.73B | +16.78% | 3.58% |
VZ | -13.17% | $178.39B | +2.59% | 6.38% |
PPC | -11.34% | $10.57B | +30.66% | 0.00% |
AWK | -10.21% | $26.90B | +6.78% | 2.27% |
HUSA | -9.75% | $22.94M | -6.82% | 0.00% |
SO | -9.56% | $99.90B | +17.18% | 3.20% |
SBAC | -9.33% | $24.80B | +17.58% | 1.81% |
LMT | -8.49% | $107.45B | -1.82% | 2.85% |
KMB | -8.20% | $42.44B | -7.46% | 3.88% |
AMT | -8.04% | $101.95B | +12.04% | 3.05% |
KR | -7.69% | $47.56B | +43.04% | 1.79% |
CL | -7.67% | $71.89B | -8.58% | 2.28% |
AQB | -7.19% | $2.84M | -54.35% | 0.00% |
CHD | -7.19% | $23.34B | -8.58% | 1.22% |
PG | -6.92% | $374.80B | -3.07% | 2.56% |
HTO | -6.78% | $1.77B | -4.41% | 3.14% |
RPRX | -6.75% | $15.11B | +36.03% | 2.40% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CB | -0.05% | $114.25B | +11.78% | 1.31% |
TAK | -0.05% | $47.52B | +16.69% | 4.33% |
HRZN | 0.11% | - | - | 18.58% |
ADC | 0.12% | $7.96B | +16.81% | 4.20% |
GIFI | 0.14% | $110.16M | +11.86% | 0.00% |
ADM | 0.16% | $24.97B | -14.01% | 3.89% |
LNTH | -0.17% | $5.64B | +1.49% | 0.00% |
VOD | 0.19% | $25.87B | +18.94% | 4.63% |
CRVO | -0.21% | $52.65M | -64.66% | 0.00% |
MSEX | -0.23% | $976.83M | +4.31% | 2.48% |
TLK | -0.26% | $16.33B | -11.87% | 7.61% |
ZBH | 0.26% | $18.10B | -15.73% | 1.05% |
CAG | -0.35% | $9.74B | -28.22% | 6.87% |
LHX | 0.37% | $46.17B | +9.97% | 1.90% |
LITB | 0.40% | $21.70M | -78.27% | 0.00% |
CI | 0.44% | $87.17B | -1.29% | 1.78% |
HCA | 0.45% | $91.25B | +18.06% | 0.74% |
SJM | 0.48% | $10.19B | -12.30% | 4.52% |
TRS | 0.51% | $1.15B | +11.03% | 0.56% |
GOGL | 0.52% | $1.49B | -45.80% | 10.75% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -37.66% | $296.79M | 1.43% |
VIXY | -30.87% | $165.69M | 0.85% |
TAIL | -27.12% | $99.76M | 0.59% |
FXY | -13.23% | $815.67M | 0.4% |
BUXX | -12.73% | $318.71M | 0.25% |
IVOL | -12.64% | $349.27M | 1.02% |
STPZ | -11.53% | $450.22M | 0.2% |
XONE | -11.04% | $585.86M | 0.03% |
FTSD | -10.96% | $231.79M | 0.25% |
ULST | -9.96% | $662.59M | 0.2% |
USDU | -8.57% | $162.92M | 0.5% |
SPTS | -8.49% | $5.78B | 0.03% |
SCHO | -8.41% | $11.46B | 0.03% |
WEAT | -8.39% | $117.15M | 0.28% |
CTA | -8.21% | $1.06B | 0.76% |
SHYM | -7.98% | $350.04M | 0.35% |
TBLL | -7.58% | $2.13B | 0.08% |
VTIP | -7.40% | $15.34B | 0.03% |
KCCA | -7.30% | $105.63M | 0.87% |
VGSH | -7.03% | $22.80B | 0.03% |
Current Value
$7.261 Year Return
Current Value
$7.261 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
ARKG | 46.85% | $1.05B | 0.75% |
KJUL | 44.89% | $120.75M | 0.79% |
IWC | 44.30% | $824.65M | 0.6% |
XHE | 44.06% | $165.61M | 0.35% |
FYX | 44.04% | $819.32M | 0.6% |
GSSC | 44.01% | $586.95M | 0.2% |
CPRJ | 43.99% | $48.21M | 0.69% |
VTWO | 43.96% | $13.29B | 0.07% |
IWO | 43.92% | $11.48B | 0.24% |
IWM | 43.92% | $64.00B | 0.19% |
IWN | 43.34% | $10.89B | 0.24% |
PRFZ | 43.30% | $2.36B | 0.34% |
IJT | 43.27% | $6.05B | 0.18% |
GNOM | 43.17% | $44.43M | 0.5% |
KJAN | 43.13% | $289.38M | 0.79% |
SLYG | 42.86% | $3.39B | 0.15% |
SCHA | 42.83% | $17.26B | 0.04% |
SPSM | 42.78% | $11.28B | 0.03% |
USVM | 42.73% | $949.41M | 0.3% |
VIOO | 42.64% | $2.86B | 0.1% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
KFRC | 52.52% | $769.23M | -33.54% | 3.70% |
LGIH | 50.47% | $1.21B | -42.38% | 0.00% |
PDM | 48.69% | $905.69M | +0.41% | 5.14% |
RGEN | 46.23% | $6.94B | -1.98% | 0.00% |
KFY | 44.17% | $3.77B | +8.74% | 2.17% |
CYRX | 44.04% | $371.52M | +7.24% | 0.00% |
CNO | 43.05% | $3.81B | +38.71% | 1.68% |
HLMN | 42.48% | $1.41B | -19.32% | 0.00% |
VRTS | 42.05% | $1.27B | -18.89% | 4.71% |
ALGN | 41.40% | $13.66B | -21.92% | 0.00% |
ENOV | 41.28% | $1.82B | -29.69% | 0.00% |
UFPI | 41.26% | $6.03B | -10.91% | 1.35% |
DNA | 41.24% | $525.33M | -29.26% | 0.00% |
FLGT | 41.22% | $599.13M | +0.31% | 0.00% |
ABG | 40.93% | $4.80B | +7.14% | 0.00% |
OLO | 40.73% | $1.44B | +95.02% | 0.00% |
HSII | 40.71% | $918.86M | +41.10% | 1.34% |
CLNE | 40.62% | $417.66M | -29.21% | 0.00% |
UPBD | 39.87% | $1.47B | -17.00% | 6.02% |
JHG | 39.72% | $6.10B | +14.92% | 4.02% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
DFIP | 0.02% | $921.22M | 0.11% |
BAB | -0.04% | $931.18M | 0.28% |
BNDX | -0.10% | $67.37B | 0.07% |
TFLO | 0.10% | $6.83B | 0.15% |
USFR | 0.18% | $18.51B | 0.15% |
BIL | -0.21% | $42.87B | 0.1356% |
USTB | -0.21% | $1.29B | 0.35% |
TIPZ | 0.25% | $94.68M | 0.2% |
CARY | 0.37% | $347.36M | 0.8% |
GOVI | -0.37% | $927.22M | 0.15% |
FLGV | -0.41% | $1.01B | 0.09% |
GOVZ | 0.41% | $270.29M | 0.1% |
AGGH | -0.45% | $323.99M | 0.29% |
FMHI | 0.45% | $752.95M | 0.7% |
STOT | -0.48% | $253.88M | 0.45% |
GSY | -0.50% | $2.73B | 0.22% |
VGLT | 0.50% | $9.82B | 0.04% |
GSST | 0.58% | $918.38M | 0.16% |
JUCY | -0.60% | $271.76M | 0.6% |
JPLD | 0.61% | $1.76B | 0.24% |
Yahoo
FORT MYERS, Fla., July 01, 2025--NeoGenomics will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025.
Yahoo
FORT MYERS, Fla., June 30, 2025--NeoGenomics launched PanTracer™ Tissue, a next-generation solid tumor profiling assay, with the option to add HRD testing.
Finnhub
NeoGenomics, Inc. announced the launch of PanTracer?? Tissue, a next-generation solid tumor profiling assay, including the option to add testing for homologous recombination deficiency . These new...
SeekingAlpha
AMG GW&K Small Cap Value Fund Q1 2025 Commentary
Yahoo
NeoGenomics’ first quarter results saw revenue growth, but sales came in below market expectations, leading to a significant negative market reaction. Management attributed the quarter’s performance to strong clinical test volume growth and increased adoption of next-generation sequencing (NGS) products, partially offset by continued headwinds in the non-clinical pharma segment. CEO Tony Zook described the quarter as confirming existing strengths, highlighting, “The NGS growth above market…was c
Yahoo
FORT MYERS, Fla., June 24, 2025--NeoGenomics announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025.